Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881831 | 0.88 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1LTB4RALDH1A1 | |
| SCHEMBL13881592 | 0.85 | MAPK1 (0.40) | CYSLTR2CYSLTR1LTB4RALDH1A1SMN1; SMN2 | |
| SCHEMBL13881593 | 0.83 | LTB4R (0.46) | CYSLTR2CYSLTR1LTB4RALDH1A1SMN1; SMN2 | |
| SCHEMBL4569126 | 0.81 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1LTB4RALDH1A1SMN1; SMN2 | |
| SCHEMBL2206208 | 0.79 | HPGD (0.43) | CYSLTR2CYSLTR1HPGD | |
| SCHEMBL13881830 | 0.79 | L3MBTL1 (0.44) | LTB4RSMN1; SMN2HPGD | |
| SCHEMBL27996046 | 0.77 | HPGD (0.51) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL25823428 | 0.76 | L3MBTL1 (0.49) | LTB4RALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL2204373 | 0.75 | SMN1; SMN2 (0.47) | LTB4RSMN1; SMN2LMNAHPGD | |
| SCHEMBL29818765 | 0.75 | SMN1; SMN2 (0.47) | LTB4RSMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CYSLTR2 456/4885CYSLTR1 417/4885LTB4R 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.